The Board of Probi appoints Anita Johansen as Interim CEO

2022-12-08 08:45:00

Anita Johansen holds the position of Vice President Research & Development with Probi since April 2022 and has a strong scientific background as well as a significant experience in global management.

Probi has initiated a search for a new CEO.

"On behalf of the Board of Directors, I thank Tom for the work he accomplished during the past years as CEO of Probi, and the way he showed commitment and loyalty to the company", said Jean-Yves Parisot, Chairman of the Board.

This information is information that Probi AB is obliged to make public according to the EU's Market Abuse Regulation. The information was submitted, through the care of the contact persons below, for publication on 8 December 2022 at 8.45 am CET. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:
Jean-Yves Parisot, Chairman of the Board, Probi, Tel: +33 678 69 58 09
Henrik Lundkvist, CFO, Probi, Tel +46 46 286 89 41, e-mail:

Probi[®] is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 658 m in 2021. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,800 shareholders on December 31, 2021.